Abstract
Background/Objectives
The prevalence of myopia is higher in preterm infants who underwent laser photocoagulation (LPC) for retinopathy of prematurity (ROP). The aim of this study was to investigate factors associated with myopia in preterm infants who undergo LPC for ROP.
Subjects/Methods
We retrospectively analysed the medical records of preterm infants born at Kyushu University Hospital (October 2008–March 2018) at ≤32 weeks of gestational age or with birth weight ≤1500 g. We evaluated the associations between nine clinical factors and the spherical equivalent at 1-year corrected age by performing multivariable linear regression in LPC-treated ROP patients.
Results
Among the 485 infants enroled, 76 developed ROP requiring treatment. Of these, 71 underwent LPC, which was provided to 63 infants as the primary treatment (LPC alone or the combination therapy of LPC and intravitreal injection of bevacizumab [IVB]) and to eight infants as additional LPC after IVB monotherapy. The results of a refractive examination at 1-year corrected age were available for 110 eyes of 56 infants (78.9%). The mean ± standard deviation of the SE value was −0.5 ± 3.0 dioptres (D). Multivariable linear regression analysis revealed a significant association between laser spot count and SE value (ß = −0.081 ± 0.040 D per 100 spots [mean ± standard error], p = 0.045).
Conclusions
Our results suggest that an increased laser spot count observed during ROP treatment associates with myopia.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Shah PK, Prabhu V, Karandikar SS, Ranjan R, Narendran V, Kalpana N. Retinopathy of prematurity: Past, present and future. World J Clin Pediatr. 2016;5:35–46.
Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group. final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233–50.
Ling CS, Fleck BW, Wright E, Anderson C, Laing I. Diode laser treatment for retinopathy of prematurity: Structural and functional outcome. Br J Ophthalmol. 1995;79:637–41.
Davitt BV, Dobson V, Good WV, Hardy RJ, Quinn GE, Siatkowski RM, et al. Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity. Ophthalmology. 2005;112:1564–8.
Quinn GE, Dobson V, Davitt BV, Hardy RJ, Tung B, Pedroza C, et al. progression of myopia and high myopia in the early treatment for retinopathy of prematurity study. findings to 3 years of age. Ophthalmology. 2008;115:1058–.e1.
Dhawan A, Dogra M, Vinekar A, Gupta A, Dutta S. Structural sequelae and refractive outcome after successful laser treatment for threshold retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 2009;45:356–61.
Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.
VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology. 2017;124:619–33.
Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity. Ophthalmology. 2015;122:1008–15.
Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial. JAMA Ophthalmol. 2014;132:1327–33.
Huang Q, Zhang Q, Fei P, Xu Y, Lyu J, Ji X, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: Anatomic outcomes and influencing factors. Ophthalmology. 2017;124:1156–64.
Fielder AR, Quinn GE. Myopia of prematurity: Nature, nurture, or disease? Br J Ophthalmol. 1997;81:2–3.
O’Connor AR, Stephenson T, Johnson A, Tobin MJ, Moseley MJ, Ratib S, et al. Long-term ophthalmic outcome of low birth weight children with and without retinopathy of prematurity. Pediatrics. 2002;109:12–18.
Yang CS, Wang AG, Shih YF, Hsu WM. Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age. Acta Ophthalmol. 2013;91:e276–e282.
Chan-Ling T, Gole GA, Quinn GE, Adamson SJ, Darlow BA. Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective. Prog Retin Eye Res. 2018;62:77–119.
Houston SK, Wykoff CC, Berrocal AM, Hess DJ, Murray TG. Laser treatment for retinopathy of prematurity. Lasers Med Sci. 2013;28:683–92.
Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684–94.
Ittiara S, Blair MP, Shapiro MJ, Lichtenstein SJ. Exudative retinopathy and detachment: A late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J Aapos. 2013;17:323–5.
Mataftsi A, Koulali E, Papageorgiou E, Ziakas N, Brazitikos P. Letter to the Editor: Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retin. 2017;48:372.
Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ, Yoon H, Blair MP. Reactivation of retinopathy of prematurity three years after treatment with bevacizumab. Ophthalmic Surg Lasers Imaging Retin. 2017;48:255–9.
Katoch D, Sanghi G, Dogra MR, Beke N, Gupta A. Structural sequelae and refractive outcome 1 year after laser treatment for type 1 prethreshold retinopathy of prematurity in Asian Indian eyes. Indian J Ophthalmol. 2011;59:423–6.
Larsson EK, Rydberg AC, Holmström GE. A population-based study of the refractive outcome in 10-year-old preterm and full-term children. Arch Ophthalmol. 2003;121:1430–6.
Smith LE, Hellström A, Stahl A, Fielder A, Chambers W, Moseley J, et al. Development of a retinopathy of prematurity activity scale and clinical outcome measures for use in clinical trials. JAMA Ophthalmol. 2019;137:305–11.
McNamara JA. Laser treatment for retinopathy of prematurity. Curr Opin Ophthalmol. 1993;4:76–80.
Roohipoor R, Karkhaneh R, Riazi Esfahani M, Alipour F, Haghighat M, Ebrahimiadib N, et al. Comparison of refractive error changes in retinopathy of prematurity patients treated with diode and red Lasers. Ophthalmologica. 2016;235:173–8.
Sanghi G, Dogra MR, Vinekar A, Gupta A. Frequency-doubled Nd:YAG (532 nm green) versus diode laser (810 nm) in treatment of retinopathy of prematurity. Br J Ophthalmol. 2010;94:1264–5.
Chhabra K, Kaur P, Singh K, Aggarwal A, Chalia D. Outcome of solid-state 532 nm green laser in high-risk retinopathy of prematurity at a tertiary care centre in India. Int Ophthalmol. 2018;38:287–91.
Dhingra D, Katoch D, Dutta S, Samanta R, Aggarwal K, Dogra MR. Change in the incidence and severity of retinopathy of prematurity (ROP) in a neonatal intensive care unit in Northern India after 20 years: Comparison of two similar prospective cohort studies. Ophthalmic Epidemiol. 2019;26:169–74.
Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. JAMA. 2015;314:1039–51.
Acknowledgements
This study was supported by a grant from Japan’s MEXT KAKENHI (No. 19K18846) to MA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mori, Y., Arima, M., Ueda, E. et al. Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity. Eye 35, 2820–2825 (2021). https://doi.org/10.1038/s41433-020-01321-z
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41433-020-01321-z
This article is cited by
-
Therapeutic outcomes of ranibizumab for zone ii stage 2 retinopathy of prematurity with plus disease
Japanese Journal of Ophthalmology (2025)
-
Development of myopia in laser-treated ROP infants: prematurity or laser photocoagulation?
International Ophthalmology (2022)
-
Risk factors for early-onset high myopia after treatment for retinopathy of prematurity
Japanese Journal of Ophthalmology (2022)
